{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:04:20Z","timestamp":1784282660366,"version":"3.55.0"},"reference-count":40,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by substantial biological heterogeneity and variable clinical outcomes. Reliable prognostic tools are needed to improve risk stratification following neoadjuvant chemotherapy (NACT). This study aimed to evaluate the association of the Clinical\u2013Pathologic Stage, Estrogen\/Grade (CPS-EG) score with pathological complete response (pCR) and survival outcomes in patients with locally advanced TNBC treated with NACT. Methods: In this multicenter retrospective cohort study, 690 patients with locally advanced TNBC treated with NACT between 2010 and 2024 at 25 oncology centers were included. Patients were categorized according to CPS-EG score (\u22643 vs. &gt;3). Associations between CPS-EG score, clinicopathological characteristics, pCR, disease-free survival (DFS), and overall survival (OS) were analyzed. Survival outcomes were evaluated using Kaplan\u2013Meier and Cox regression analyses. Results: Patients with a CPS-EG score &gt; 3 had significantly lower pCR rates and higher recurrence rates compared with those with a CPS-EG score \u2264 3 (p &lt; 0.001 for both). Five-year OS rates were 83.7% and 54.1% in the CPS-EG \u2264 3 and &gt; 3 groups, respectively, while the corresponding five-year DFS rates were 76.4% and 51.9% (p &lt; 0.001 for both). In the multivariable analysis, CPS-EG &gt; 3 remained independently associated with worse OS (HR 1.46, 95% CI 1.08\u20131.98, p = 0.015) and DFS (HR 1.73, 95% CI 1.26\u20132.38, p &lt; 0.001). Conclusions: A higher CPS-EG score is associated with a lower likelihood of achieving pCR and poorer long-term survival outcomes in patients with locally advanced TNBC treated with NACT. The CPS-EG score represents a simple and readily available tool that may support risk stratification and clinical decision-making in routine practice.<\/jats:p>","DOI":"10.3390\/cancers18142302","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:00:52Z","timestamp":1784278852000},"page":"2302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1404-8983","authenticated-orcid":false,"given":"Neslihan","family":"\u00d6zyurt","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ordu University, Ordu 52200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Alkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, Mu\u011fla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"G\u00fclba\u011fc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Sakarya University, Sakarya 54187, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Seyyar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Kocaeli University, \u0130zmit 41000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-2475","authenticated-orcid":false,"given":"Esra","family":"Asik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u015eahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Celal Bayar University, Manisa 45140, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-917X","authenticated-orcid":false,"given":"Mehmet","family":"T\u00fcrker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, \u00c7ukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-3291","authenticated-orcid":false,"given":"O\u011fuzcan","family":"K\u0131n\u0131ko\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Training and Research Hospital, \u0130stanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-1412","authenticated-orcid":false,"given":"Tahir","family":"Yerlikaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Training and Research Hospital, Antalya 07100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulhan","family":"Dinc","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Okmeydan\u0131 Training and Research Hospital, \u0130stanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9753-8517","authenticated-orcid":false,"given":"Ali","family":"Ayta\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Kalkan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Dicle University, Diyarbak\u0131r 21280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senar","family":"Ebin\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Diyarbak\u0131r Training and Research Hospital, Diyarbak\u0131r 21070, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1998-3150","authenticated-orcid":false,"given":"\u0130lkay","family":"G\u00fclt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bak\u0131rk\u00f6y Sadi Konuk Training and Research Hospital, \u0130stanbul 34147, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-3144","authenticated-orcid":false,"given":"Merve","family":"Keskink\u0131l\u0131\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Dokuz Eyl\u00fcl University, \u0130zmir 35340, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0045-8009","authenticated-orcid":false,"given":"Zehra Sucuo\u011flu","family":"\u0130\u015fleyen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Bezm-i Alem Vak\u0131f University, \u0130stanbul 34093, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4629-6815","authenticated-orcid":false,"given":"Dilek","family":"\u00c7a\u011flayan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Necmettin Erbakan University, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-9679","authenticated-orcid":false,"given":"Alper","family":"T\u00fcrkel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Recep Tayyip Erdo\u011fan University, Rize 53100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teoman","family":"\u015eakalar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kahramanmara\u015f Necip Faz\u0131l City Hospital, Kahramanmara\u015f 46050, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-248X","authenticated-orcid":false,"given":"Serhat","family":"Sekmek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilg\u00fcn","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, F\u0131rat University, Elaz\u0131\u011f 23119, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-211X","authenticated-orcid":false,"given":"Sinem","family":"Akbas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ko\u00e7 University, \u0130stanbul 34010, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-7739","authenticated-orcid":false,"given":"Kerem","family":"Okutur","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, \u0130stanbul Arel University, \u0130stanbul 34537, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-5432","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zveren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ac\u0131badem Kent Hospital, \u0130zmir 35630, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beng\u00fc","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ankara University, Ankara 06570, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan \u00d6nder","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Sel\u00e7uk University, Konya 42130, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0853-4096","authenticated-orcid":false,"given":"\u0130smail","family":"Beyp\u0131nar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Alanya Al\u00e2eddin Keykubat University, Antalya 07425, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Can \u015eanc\u0131","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Kocaeli University, \u0130zmit 41000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahattin Engin","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Necmettin Erbakan University, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Hac\u0131bekiro\u011flu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Sakarya University, Sakarya 54187, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"\u00c7abuk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Kocaeli University, \u0130zmit 41000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elanur","family":"Karaman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Acar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Celal Bayar University, Manisa 45140, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4642-3693","authenticated-orcid":false,"given":"Semra","family":"Payda\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, \u00c7ukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Karakurt","family":"Ery\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Necmettin Erbakan University, Konya 42080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgin","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ayd\u0131n Adnan Menderes University, Ayd\u0131n 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Oru\u00e7","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Dicle University, Diyarbak\u0131r 21280, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bak\u0131rk\u00f6y Sadi Konuk Training and Research Hospital, \u0130stanbul 34147, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih Sel\u00e7uk","family":"Biricik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, School of Medicine, Ko\u00e7 University, \u0130stanbul 34010, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-3460","authenticated-orcid":false,"given":"Derya K\u0131vrak","family":"Salim","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Antalya Training and Research Hospital, Antalya 07100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"Tanr\u0131verdi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mu\u011fla S\u0131tk\u0131 Ko\u00e7man University, Mu\u011fla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/cncr.23844","article-title":"Guideline Implementation for Breast Healthcare in Low- and Middle-Income Countries: Overview of the Breast Health Global Initiative Global Summit 2007","volume":"113","author":"Anderson","year":"2008","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular Alterations in Triple-Negative Breast Cancer: The Road to New Treatment Strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Domergue, C., Martin, E., Lemari\u00e9, C., J\u00e9z\u00e9quel, P., Frenel, J.S., Augereau, P., Campone, M., and Patsouris, A. (2022). Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14102509"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e70267","DOI":"10.1002\/cncr.70267","article-title":"Receipt of Guideline-Concordant Local and Chemotherapy-Based Systemic Therapy for Patients with Triple-Negative Breast Cancer: 10-Year Survival Outcomes in a Multi-State Population-Based Analysis","volume":"132","author":"Lipscomb","year":"2026","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"26406","DOI":"10.18632\/oncotarget.25413","article-title":"Triple-Negative Breast Cancer Subtypes and Pathologic Complete Response Rate to Neoadjuvant Chemotherapy","volume":"9","author":"Santonja","year":"2018","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1200\/JCO.2007.11.5352","article-title":"Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated with Neoadjuvant Therapy","volume":"26","author":"Jeruss","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-016-3800-5","article-title":"Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Triple-Negative Breast Cancer among BRCA1 Mutation Carriers and Non-Carriers","volume":"157","author":"Friedman","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Oshi, M., Newman, S., Murthy, V., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., and Takabe, K. (2020). ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. Cancers, 12.","DOI":"10.3390\/cancers12102758"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151634","DOI":"10.1016\/j.anndiagpath.2020.151634","article-title":"Predictive Markers for Pathological Complete Response after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer","volume":"49","author":"Noel","year":"2020","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of Residual Breast Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"van den Ende, N.S., Nguyen, A.H., Jager, A., Kok, M., Debets, R., and van Deurzen, C.H.M. (2023). Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032969"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor-Infiltrating Lymphocytes Are Prognostic in Triple-Negative Breast Cancer and Predictive for Trastuzumab Benefit in Early Breast Cancer: Results from the FinHER Trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.2010.31.8469","article-title":"Validation of a Novel Staging System for Disease-Specific Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy","volume":"29","author":"Mittendorf","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1158\/1078-0432.CCR-17-2947","article-title":"Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor","volume":"24","author":"Loibl","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2021.05.027","article-title":"Utility of the CPS+EG Scoring System in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy","volume":"153","author":"Solbach","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-Analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.breast.2018.03.010","article-title":"Validation of the CPS+EG and Neo-Bioscore Staging Systems after Preoperative Systemic Therapy for Breast Cancer in a Single Center in China","volume":"40","author":"Xu","year":"2018","journal-title":"Breast"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1590\/1806-9282.20210249","article-title":"Prognostic Factors in Triple-Negative Breast Cancer: A Retrospective Cohort","volume":"67","author":"Costa","year":"2021","journal-title":"Rev. Assoc. Med. Bras."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1\/2 and High-Risk Early Breast Cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.annonc.2025.03.010","article-title":"Final Survival Results from the PENELOPE-B Trial Investigating Palbociclib versus Placebo for Patients with High-Risk HR+\/HER2\u2212 Breast Cancer and Residual Disease after Neoadjuvant Chemotherapy","volume":"36","author":"Loibl","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1016\/j.annonc.2021.08.480","article-title":"199TiP Phase III Post-Neoadjuvant Study Evaluating Sacituzumab Govitecan (SG), an Antibody Drug Conjugate in Primary HER2-Negative Breast Cancer Patients with High Relapse Risk after Standard Neoadjuvant Treatment: SASCIA","volume":"32","author":"Hanusch","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"pkaf022","DOI":"10.1093\/jncics\/pkaf022","article-title":"Revisiting Surrogacy of Pathological Complete Response for Long-Term Survival in Triple-Negative Breast Cancer","volume":"9","author":"Yoshino","year":"2025","journal-title":"JNCI Cancer Spectr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamaoncol.2022.3755","article-title":"Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations","volume":"8","author":"Conforti","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101006","DOI":"10.1016\/j.modpat.2026.101006","article-title":"Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort","volume":"39","author":"Denkert","year":"2026","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.09.022","article-title":"Utility of the CPS+EG Staging System in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy","volume":"53","author":"Lederer","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10549-019-05314-9","article-title":"Locoregional Risk Assessment after Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer: Clinical Utility of the CPS+EG Score","volume":"177","author":"Michel","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"\u00d6ner, \u0130., T\u00fcrkel, A., \u0130nci, B.K., Tolunay, P.K., Ate\u015f, \u00d6., and Kara\u00e7in, C. (2024). Impact of the CPS-EG Score as a New Prognostic Biomarker in Triple-Negative Breast Cancer Patients Who Received Neoadjuvant Chemotherapy. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-13100-0"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"114037","DOI":"10.1016\/j.ejca.2024.114037","article-title":"Prognostic Stratification Ability of the CPS+EG Scoring System in HER2-Low and HER2-Zero Early Breast Cancer Treated with Neoadjuvant Chemotherapy","volume":"202","author":"Roussot","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16899","DOI":"10.1038\/s41598-024-67795-z","article-title":"Efficacy and Prognosis of HER2-Low and HER2-Zero in Triple-Negative Breast Cancer after Neoadjuvant Chemotherapy","volume":"14","author":"Shi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4048\/jbc.2024.0268","article-title":"Impact of HER2-Low Status on Pathologic Complete Response and Survival Outcome among Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy","volume":"28","author":"Lee","year":"2025","journal-title":"J. Breast Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103831","DOI":"10.1016\/j.breast.2024.103831","article-title":"The \u201cLows\u201d: Update on ER-Low and HER2-Low Breast Cancer","volume":"78","author":"Fusco","year":"2024","journal-title":"Breast"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.1038\/s41598-024-80587-9","article-title":"Author Correction: The Prognostic Impact of HER2 Status in Early Triple-Negative Breast Cancer: A Turkish Oncology Group (TOG) Study","volume":"15","author":"Alkan","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10549-016-4008-4","article-title":"Assessment of Pathologic Response and Long-Term Outcome in Locally Advanced Breast Cancers after Neoadjuvant Chemotherapy: Comparison of Pathologic Classification Systems","volume":"160","author":"Choi","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/annonc\/mdf039","article-title":"Very Young Women (<35 Years) with Operable Breast Cancer: Features of Disease at Presentation","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00292-022-01139-4","article-title":"New Treatment Options for Metastatic HER2-Low Breast Cancer: Consequences for Histopathological Diagnosis","volume":"44","author":"Denkert","year":"2023","journal-title":"Pathologie"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T09:17:28Z","timestamp":1784279848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":40,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142302"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142302","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}